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Abstract
Two HIV infected patients not receiving Highly Active Antiretroviral Treatment (HAART) presented with epidemic 
Kaposi’s sarcoma of the oral cavity. One patient initially refused HAART, but when the lesion became large enough 
to be noticeable he agreed to HAART associated with excision of the intraoral lesion by CO2 laser. The other patient 
developed KS and progressed to AIDS at two years after ceasing HAART due to adverse effects; he was referred to 
hospital for renewed administration of HAART. In both cases, the lesions observed in the oral cavity were the first 
clinical manifestation of AIDS. These reports underline the close relationship between the use of HAART and the 
control of KS lesions, highlighting the important role of the dentist in the identification and early diagnosis of these 
oral lesions.
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Introduction 
In 1872, Moritz Kaposi described five patients with 
cutaneous-mucous red-violet lesions that he designated 
“multiple idiopathic hemorrhagic sarcomas”. This con-
dition later became known as Kaposi’s sarcoma (KS), 
the name proposed by Sternberg in 1912 (1). KS is a ma-
lignant, multifocal systemic disease that originates in the 
vascular endothelium and follows a variable course. The 
most frequent localization is on the skin but it is also ob-
served in mucous membranes, lymphatic system, and other 
organs (especially lung, liver, intestine, and stomach). Four 
clinical forms have been classified: classic KS, iatrogenic 
immunosuppression KS, Africa-endemic KS and epidemic 
KS (EKS), associated with HIV infection. EKS remains 
the most frequent malignant disease indicating AIDS. It 
was first reported in the 1980s and is more frequent in ho-
Indexed in: 
- Science Citation Index Expanded
- Journal Citation Reports
- Index Medicus, MEDLINE, PubMed
- Excerpta Medica, Embase, SCOPUS, 
- Indice Médico Español
mosexual males (MSM, Men who have Sex with Men) or 
bisexual males with AIDS (around 25%) than in other risk 
groups (1-5%) (2). In the USA, there has been a reduction 
in EKS cases of more than 66% since the introduction of 
HAART (3). In Spain, 5.3% of patients diagnosed with 
AIDS between 2003 and 2006 had EKS (4). 
All forms of KS are due to infection by human herpesvirus 
type 8 (HHV-8), also known as KS-associated herpesvirus 
(KSHV), which is transmitted via sexual route, blood, or 
saliva (5). In HIV-infected patients, presence of KS pro-
vides definitive diagnosis of AIDS. However, despite the 
therapeutic effect of HAART on KS, the disease continues 
to progress in some patients and specific treatment of 
the tumor with liposomal anthracyclines (daunorubicin 
and doxorubicin) is needed. The association of HAART 
with paclitaxel (Taxol®, Bristol-Myers Squibb Company, 
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NY, USA) is a third therapeutic option when the disease 
progresses despite HAART treatment and involves other 
organs (6). 
Since the introduction of the above therapies, the pro-
portion of AIDS patients with oral KS has fallen from 
around a third to less than 20% in developed countries, 
due to new therapies (7). We present two cases of EKS 
of oral cavity as the first clinical manifestation of AIDS 
in patients who were not receiving HAART at the time 
of their EKS diagnosis. Their subsequent clinical course 
is also reported.
Case reports  
- Case report 1
A 34-year-old MSM, diagnosed with HIV infection in 1989 
and with syphilis and hepatitis B in 1999. He reported that 
he did not consume tobacco or other drugs. In April 1999, 
he had undergone a fine needle aspiration (FNA) biopsy of 
the right submaxillary gland that revealed a mesenchymal 
tumor with no atypical mitosis. The histopathology report 
identified a major salivary gland with KS. In June 1999, 
he was found to have a TCD4+ lymphocyte count/% of 
1.111 cells/mm3/30%, CD4/CD8 ratio of 0.6, and HIV-1 
RNA viral load of 10318 copies/ml (bDNA). The patient 
was diagnosed with stage C1 HIV infection (AIDS), and 
his physician at the Sexually Transmitted Disease Clinic 
recommended HAART treatment with ddI (didanosine), 
d4T(estavudine), and efavirenz. However, the patient re-
fused this therapy, citing fear of adverse effects. 
In July 1999, he returned to our Oral Medicine Clinic at 
the Dental School with a 4-month-old reddish-blue lesion, 
1.5 x 1 cm in size, of soft consistency and mildly painful 
on palpation, on the marginal gingiva at teeth 1.4, 1.5, 
and 1.6 (Fig. 1a). Tooth 1.5 had a periodontal pocket of 8 
mm but X-ray showed no bone loss (Fig. 1b). The patient 
was strongly recommended to commence HAART for 
suspicion of KS but again refused this therapy. He missed 
the appointment made for a biopsy, finally returning six 
months later in January 2000. Examination revealed an 
almost doubling in size of the intraoral lesion (2.5cm x 
2cm) and multiple macular lesions on skin of abdomen, 
left groin, and sole of right foot, suggesting EKS (Figs. 
2a-d). The count/percentage of  TCD4+ lymphocyte 
count/percentage was 858 cells/ml/21.5%, the CD4/CD8 
ratio was 0.4, and the HIV-1 RNA viral load was 14,919 
copies/ml. He was told that although his immunological 
situation did not appear highly compromised, the HIV 
disease was progressing rapidly and he was again urged to 
start HAART. He returned to our clinic one month later, 
reporting that the lesion was larger and noticeable when 
he laughed or talked. For esthetic reasons, the patient 
agreed to surgical excision of the lesion with CO2 laser 
(20W) to prevent bleeding. Tooth 1.5 was extracted in the 
same surgical procedure. The pathology report confirmed 
the lesion as KS and the patient finally agreed to receive 
HAART with ddI (didanosine), d4T (estavudine), and 
efavirenz. He was followed up at one month and at three 
months and no signs of recurrence were observed. At the 
three-month follow-up, the patient had non-detectable 
viral load and the TCD4+ lymphocyte count had risen 
to 954 cells/mm3.
- Case Report 2
We present the case of a 23-year-old male diagnosed with 
HIV infection in 1986 and with a history of hepatitis B 
and oral candidiasis (February 2002). He reported being a 
regularly cannabis user, smoker of 10 cigs/day, and a non-
drinker of alcohol. He received HAART with nelfinavir 
+d4T (stavudine) +3TC (lamivudine) from 1999 until 
October 2000, when he stopped this treatment because of 
adverse effects. When he first visited our Oral Medicine 
Clinic in March 2002, he was found to have a TCD4+ 
lymphocyte count/% of 8 cells/ml/0.4%, CD4/CD8 ratio of 
0.0 and HIV-1 RNA viral load of 9308 copies/ml (bDNA). 
The intraoral examination revealed several purplish macu-
lar/nodular lesions in the upper palatal area (bilateral) at 
teeth 1.6-1.8 and 2.6-2.8; and in the lower buccal gingiva 
Fig. 1. CASE 1: (a.) Four-month-old reddish-bluish lesion on the marginal gingiva at teeth 1.4-1.5 and 1.6.  (b) 
X-ray showed no bone loss at tooth 1.5.
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Fig. 2. CASE 1: (a)- Increase of tumor 6 months later (2.5cm x 2cm). (b,c,d) Multiple macular lesions on skin 
of abdomen and foot.
Fig. 3. CASE 2: (a,b). Several purplish macular/nodular lesions in upper palatal 
area. (c) Macular lesion on lower buccal gingiva at tooth 4.6. (d) Isolated nodule on 
buccal gingiva at tooth 2.4. 
.
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at tooth 4.6, with an isolated nodule on buccal gingiva 
at tooth 2.4 (Figs 3a-d). The lesions were clinically com-
patible with KS and this diagnosis was confirmed by the 
histopathological study. The patient reinitiated HAART 
with AZT (zidovudine), d4T (stavudine), and abacavir, 
which he has continued to receive to date with a good 
immunological and virological response. In December 
2002, immune system recovery was observed, with TCD4+ 
and TCD8+ lymphocyte counts/% of 165 cells/ml/7% and 
1538 cells/ml/63%, respectively, CD4/CD8 ratio of 0.1, 
and HIV-1 RNA viral load of <50 copies/ml (bDNA). 
The intraoral KS lesions had completely disappeared with 
no need for further treatment, despite the absence in his 
therapeutic regimen of any protease inhibitor (PI) to avoid 
the adverse effects, probably related to nelfinavir, which 
had led the patient to abandon HAART. 
Discussion 
KS is the malignant oral neoplasia most frequently asso-
ciated with HIV-infection, although there has been a steep 
decline in its incidence since the introduction of HAART 
(8,9). It mainly affects MSM and is indicative of AIDS, 
with the highest incidence of KS lesions in the 30-38 year 
age group with 5 cases /100 people/yr (9).
HHV-8, immunosuppression, genetic predisposition, 
direct effect of HIV, coinfection of pathogens by sexual 
route, and production cell proliferation-inducing cytoki-
nes, among other factors, all play a role in the pathogeny 
of KS (10).  
Oral cavity lesions appear as bluish-red or purple ma-
cular, papular, or nodular lesions that can ulcerate and 
cause local destruction, with the palate and gingiva as 
the most frequent oral sites (11). The ulceration and local 
destruction caused by KS lesions sometimes mandates the 
extraction of teeth that have lost support, as in our first 
case presented here. Some authors have reported the first 
clinical sign of KS to be in oral cavity in 20% of cases 
and simultaneously in oral cavity and skin or other sites 
in 70% of cases (11,12).
There is currently no curative therapy for AIDS-related 
EKS (9). The utilization of HAART, including at least one 
PI, not only stabilizes or slows the progression of lesions 
but can also reduce or eradicate them (7,13). More recent 
studies have postulated that the immune response may 
contribute to the reduction in the incidence of EKS during 
HAART, explaining the frequent and rapid resolution of 
EKS with initiation of this therapy (14,15). In the two 
present cases, the HAART did not include a PI, and there 
was even a total remission of symptoms in the second case 
with no need for any other therapeutic measure.
Interestingly, an HIV viral load of >5000 cop/cm3 was 
associated with an increased risk of EKS but there was 
no such association with a sudden fall in the TCD4+ lym-
phocyte count (9). Both of our patients had viral loads 
of more than 9,000 copies/ml but their CD4+ lymphocyte 
counts were very different, with a count above 1,000 cells/
mm3 in the first case.
In vivo and in vitro studies have demonstrated that the 
PIs indinavir and saquinavir have direct antiangiogenic 
activity (16) and that the PI ritonavir has anti-tumor and 
anti-KS activity at the blood concentrations in HAART-
treated patients (9,17). HAART produces a fall in blood 
levels of HHV-8, presumably due to a reduction in HIV 
proliferation, HIV/HHV-8-mediated oncogenesis, and 
HIV-induced immunosuppression (13).
Numerous approaches have been adopted towards KS 
lesions in the oral cavity, including local radiation (16), 
intralesional injections of  vinblastine or 3% sodium 
tetradecyl sulfate (18), laser therapy, surgical excision, 
cytotoxic alkaloids (vinblastine, vincristine, and vino-
relbine), bleomycin, anthracyclines, paclitaxel (19), and 
liposomal anthracyclines (20). At the diagnosis of these 
patients, the decision was taken not to use surgical lesion 
with CO2 laser. In the first patient this was because of the 
size and location of the tumor and to improve control of 
the hemorrhage, and in the second patient because lesions 
slowly reduced with the commencement and continuation 
of the HAART.
Only five agents are approved by the FDA for KS 
treatment: alitretinoin gel (topical administration), liposo-
mal daunorubicin, liposomal doxorubicin, paclitaxel, and 
interferon-alpha (all four as systemic therapy) (21).
A series of drugs with high antiangiogenic effects are emer-
ging that may be relevant in the short-term management 
of KS, such as thalidomide and matrix metalloproteinases. 
Other drugs under study include retinoids, cidofovir, and 
IM-862(dipeptide l-glutamine l-tryptophane with antian-
giogenity activity) (9). 
 This paper confirms the importance of dentists being able 
to identify lesions associated with HIV infection. The onset 
of EKS lesions in the oral cavity can be the first clinical 
manifestation of AIDS, indicating the immediate initiation 
of HAART in these patients.
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